Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Meanwhile, Dupixent from Regeneron and Sanofi is set to bring in $13.5B this year, up from $11.6B in 2023. The drug is set to ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

An experimental COPD drug from Sanofi and Regeneron showed mixed results in a pair of studies, sending the companies' shares ...

Our analyst team just revealed what they believe are the 10 best ... of new drugs. At the time, GSK made a $300 million equity investment in 23andMe, which is more than the amount Regeneron ...

So Dupixent should remain one of the top-selling drugs in the world for the foreseeable future, and help pull Regeneron's revenue in the right direction. The loss of patent exclusivity for Eylea ...

So far, the president has received: Supplemental oxygen An antibody cocktail developed by Regeneron (REGN ... ongoing across the world. Here's what we know about the drugs Trump has been taking ...

AbbVie's (NYSE:ABBV) autoimmune disease biologic Humira (adalimumab) and Pfizer (NYSE:PFE)/BioNTech's (BNTX) COVID-19 shot Comirnaty are projected to not make it into a list of the top 10 drugs ...